EP004 - Magnetic resonance imaging in detecting clinical significant prostate cancer - a tertiary hospital experience

Publication date: November 2019Source: European Urology Supplements, Volume 18, Issue 10Author(s): R. Rodrigues Fonseca, R. Lains Mota, I. Peyroteo, A. Bilé Silva, J.C. Santos, F. Alpoim Lopes, A. Covita, A. Canhoto, P. Monteiro, R. Nogueira, L. Abranches Monteiro
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research

Related Links:

Conclusion: By use of our nomogram, bone scans of men with prostate cancer can be avoided in a large proportion of men. PMID: 31805808 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Urology - Category: Urology & Nephrology Tags: Scand J Urol Source Type: research
Publication date: Available online 6 December 2019Source: European UrologyAuthor(s): Marloes van der Leest, Bas Israël, Rianne R.M. Engels, Jelle O. Barentsz
Source: European Urology - Category: Urology & Nephrology Source Type: research
This report describes the feasibility and short-term outcomes of an...
Source: BMC Urology - Category: Urology & Nephrology Authors: Tags: Research article Source Type: research
Abstract CLINICAL/METHODICAL ISSUE: In view of the diagnostic complexity and the large number of examinations, modern radiology is challenged to identify clinically significant prostate cancer (PCa) with high sensitivity and specificity. Meanwhile overdiagnosis and overtreatment of clinically nonsignificant carcinomas need to be avoided. STANDARD RADIOLOGICAL METHODS: Increasingly, international guidelines recommend multiparametric magnetic resonance imaging (mpMRI) as first-line investigation in patients with suspected PCa. METHODICAL INNOVATIONS: Image interpretation according to the PI-RADS criteria i...
Source: Der Radiologe - Category: Radiology Authors: Tags: Radiologe Source Type: research
ConclusionsmpMRI detected the majority of high-grade and large cancers, but had low sensitivity in the PZ, posterior, and apex and base of the gland. The high prevalence of low-volume, low-Gleason score index tumors, as well as satellite tumors in those areas, accounted for the difference.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
AbstractAccurate early detection of recurrent prostate cancer after surgical or nonsurgical treatment is increasingly relevant in the era of evolving options for salvage therapy. The importance of differentiating between local tumor recurrence, distant metastatic disease, and a combination of both in a patient with biochemical recurrence of prostate cancer is essential for appropriate treatment selection. Magnetic resonance imaging (MRI) is the best test for localization and characterization of locally residual or recurrent prostate cancer. It is essential for the radiologist involved in prostate MRI interpretation to be f...
Source: Abdominal Imaging - Category: Radiology Source Type: research
ConclusionsThis article and the accompanying video show different MRGB techniques. The advantages and disadvantages of the three biopsy techniques, as well as the clinical setting in which each biopsy strategy is being used in our hospital, are discussed. Fus-MRGB is our first choice for prostate biopsy. Direct inbore-MRGB is used in difficult lesions but is mainly used as a “problem solver” (eg, a negative biopsy with a high suspicion for clinically significant prostate cancer). In our opinion, cog-MRGB is best for sampling larger and diffuse lesions.Patient summaryThis third surgery in motion contribution sho...
Source: European Urology - Category: Urology & Nephrology Source Type: research
Publication date: Available online 29 November 2019Source: European UrologyAuthor(s): Arnaldo Stanzione, Massimo Imbriaco, Renato Cuocolo
Source: European Urology - Category: Urology & Nephrology Source Type: research
CONCLUSIONS: Incidental lesions detected in the prostate by FDG PET may represent clinically significant CaP. Referral to a urologist for further evaluation should be considered if the patient is otherwise in reasonable health. PMID: 31793859 [PubMed - as supplied by publisher]
Source: Canadian Urological Association Journal - Category: Urology & Nephrology Authors: Tags: Can Urol Assoc J Source Type: research
Publication date: Available online 25 November 2019Source: European UrologyAuthor(s): Veeru Kasivisvanathan, Francesco Giganti, Mark Emberton, Caroline M. Moore
Source: European Urology - Category: Urology & Nephrology Source Type: research
More News: Cancer | Cancer & Oncology | Hospitals | MRI Scan | Prostate Cancer | Urology & Nephrology